Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 108

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 108
---
 risks, unexpected risks may arise and previously known risks may materialize in a manner not consistent with BLAC’s preliminary risk analysis. Even though these charges may be non -cashitems and not have an immediate impact on New OSR Holdings’ liquidity, the fact that New OSR Holdings reports charges of this nature could contribute to negative market perceptions about New OSR Holdings or New OSR Holdings’ securities. In addition, charges of this nature may cause New OSR Holdings to violate net worth or other covenants to which New OSR Holdings may be subject to by virtue of New OSR Holdings obtaining post -combinationdebt financing. Accordingly, any BLAC stockholders who choose to remain stockholders of New OSR Holdings following the Business Combination could suffer a reduction in the value of their shares of common stock from any such write -downor write -downs. The valuation report of Darnatein prepared by Ghilin Accounting Corp., which was relied upon by the BLAC M&A Committee and Choloc, is based, in part, on an assumption that Darnatein will enter into a $2,000,000,000 licensing deal with a third-party. The valuation report prepared by Ghilin Accounting Corp., which was relied upon by the BLAC M&A Committee and Choloc, was prepared over two years ago, and is based, in part, on an assumption that Darnatein will enter into a $2,000,000,000 licensing deal with a third -party. The assumption is speculative, has not materialized, and may never materialize. The failure of Darnatein to enter into a $2,000,000,000 licensing deal could materially damage Darnatein’s, OSR Holdings’, and New OSR Holdings’ brands, businesses, financial goals, operations and results, all of which could have an adverse impact on the price of New OSR Holdings securities. BLAC’s Current Charter contains a waiver of corporate opportunities. Article X of the Current Charter provides that the doctrine of corporate opportunity, or any other analogous doctrine, shall not apply with respect to BLAC or any of its officers or directors in circumstances where the application of any such doctrine would conflict with any fiduciary duties or contractual obligations they may have as of the date of the Current Charter or in the future. Article X of the Current Charter also provides that, in addition to the foregoing, the doctrine of corporate opportunity shall not apply to any other corporate opportunity with respect to any of the